Literature DB >> 17033754

Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: Should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients?

R Orlando1, G Tosone, D Tiseo, M Piazza, G Portella, R Ciancia, V Martinelli, B Montante, B Rotoli.   

Abstract

The reverse seroconversion to hepatitis B virus infection has been sporadically described in onco-haematological patients receiving cytotoxic therapy or allogeneic bone marrow transplantation and can be associated with the development of acute icteric hepatitis. We present a male HBsAg-negative, anti-HBc-positive patient with Hairy Cell Leukemia who developed acute B hepatitis more than 1 year after the last course of 2-CdA and 6 months after splenectomy, while the patient was receiving therapy with alphaIFNr. The acute B hepatitis promptly responded to lamivudine therapy followed by viral clearance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033754     DOI: 10.1007/s15010-006-4150-8

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  3 in total

1.  Acute hepatitis B despite a previous high titer of anti-HBs.

Authors:  Resat Ozaras; Cem Ar; Seniz Ongoren; Bilgul Mete; Fehmi Tabak; Ali Mert; Recep Ozturk
Journal:  Hepatol Int       Date:  2010-04-09       Impact factor: 6.047

2.  Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.

Authors:  Panayiotis D Ziakas; Petros Karsaliakos; Eleftherios Mylonakis
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

3.  Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.

Authors:  Chien-Yuan Chen; Feng-Ming Tien; Aristine Cheng; Shang-Yi Huang; Wen-Chien Chou; Ming Yao; Jih-Luh Tang; Hwei-Fang Tien; Wang-Huei Sheng
Journal:  BMC Gastroenterol       Date:  2018-01-08       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.